Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
269
Views
2
CrossRef citations to date
0
Altmetric
Methodology

Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

Meng-Jie Wang1 Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, 471003, People’s Republic of China
,
Yu-Hang Zhao2 School of Medical Imaging, Hangzhou Medical College, Hangzhou, 310051, Zhejiang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-0887-9297
ORCID Icon,
Chen Fan3 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, Henan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-8481-9301
ORCID Icon,
Ying-Jie Wang3 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, Henan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0913-5166
ORCID Icon,
Xin-Qi Wang3 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, Henan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-7339-802X
ORCID Icon,
Xiang-Jun Qiu3 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, Henan, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7644-9598
ORCID Icon &
Rui-Le Shen1 Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, 471003, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 4167-4175 | Published online: 02 Oct 2021

References

  • SmolenJS, AletahaD, BartonA, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.129417936
  • McInnesIB, SchettG. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328–2337. doi:10.1016/S0140-6736(17)31472-128612747
  • ParmentierJM, VossJ, GraffC, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1):23. doi:10.1186/s41927-018-0031-x30886973
  • AlunnoA, PadjenI, FanouriakisA, BoumpasDT. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells. 2019;8(8):898. doi:10.3390/cells8080898
  • KamedaH, FujiiT, NakajimaA, et al. Japan college of rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31–40. doi:10.1080/14397595.2018.147235829718746
  • SmolenJS, LandeweRBM, BijlsmaJWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-21665531969328
  • NormanP. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–1077. doi:10.1517/13543784.2014.918604
  • AbbVie. AbbVie receives FDA approval of RINVOQ™ (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis; 2019. Available from: https://news.abbvie.com/news/press-releases/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm. Accessed 1128, 2019.
  • ConaghanPG, MyslerE, TanakaY, et al. Upadacitinib in rheumatoid arthritis: a benefit–risk assessment across a Phase III program. Drug Saf. 2021;44(5):515–530. doi:10.1007/s40264-020-01036-w33527177
  • MeasePJ, LertratanakulA, PappKA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled Phase 3 SELECT-PsA 2 study. Rheumatol Ther. 2021;8(2):903–919. doi:10.1007/s40744-021-00305-z33913086
  • MohamedMF, CampHS, JiangP, PadleyRJ, AsatryanA, OthmanAA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558. doi:10.1007/s40262-016-0419-y27272171
  • Mohamed-EslamF, KlünderMB, OthmanAA. Clinical pharmacokinetics of Upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59(5):531–544. doi:10.1007/s40262-019-00855-031867699
  • XueguX, LuoS, YangQ, et al. Development and validation of the quantitative determination of avapritinib in rat plasma by a bioanalytical method of UPLC-MS/MS. Arab J Chem. 2021;14(6):103152. doi:10.1016/j.arabjc.2021.103152
  • ZhangY, ZhuM, XieS, YeX, XueguX. Simultaneous determination of amiodarone, dronedarone, and their principal metabolites in SD rat plasma by UPLC-MS/MS and its application in pharmacokinetics. Arab J Chem. 2021;14(8):103300. doi:10.1016/j.arabjc.2021.103300
  • MohamedMF, ZengJ, MarroumPJ, SongIH, OthmanAA. Pharmacokinetics of Upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis Phase 3 trials. Clin Pharmacol Drug Dev. 2019;8(2):208–216. doi:10.1002/cpdd.46229688617
  • MohamedMF, TruemanS, FengT, AndersonJ, MarburyTC, OthmanAA. Characterization of the effect of renal impairment on Upadacitinib pharmacokinetics. J Clin Pharmacol. 2019;59(6):856–862. doi:10.1002/jcph.137530633369
  • US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD, USA: US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research; 2018. Available from: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/bioanalyticalmethodvalidation-guidance-industry. Accessed 810, 2018.
  • The technical guidelines for non clinical pharmacokinetics of drugs. Available from: http://www.nmpa.gov.cn/gsz05106/15.pdf. Accessed 922, 2021
  • HuJ, SuX-J, SiH-L, et al. Simultaneous determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma using UPLC-MS/MS method and the application in pharmacokinetics. Drug Des Devel Ther. 2021;15:2529–2541. doi:10.2147/DDDT.S314562
  • ZhouC-J, WangH-J, ZhouC-Y, et al. Establishment and verification of UPLC-MS/MS technique for pharmacokinetic drug–drug interactions of Selinexor with Posaconazole in rats. Drug Des Devel Ther. 2021;15:1561–1568. doi:10.2147/DDDT.S303928

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.